Professional Records
License Records
David D. Eveleth
License #:
S5-0006110 - Expired
Category:
Architecture
Type:
Licensed Architect
David Eveleth Phones & Addresses
-
San Diego, CA
-
70 Wellington Rd, East Brunswick, NJ 08816 (732) 967-1849
-
Orange, CT
-
Branford, CT
-
Los Angeles, CA
-
Irvine, CA
-
Mission Viejo, CA
-
Del Mar, CA
-
4868 Almondwood Way, San Diego, CA 92130 (732) 967-1849
Work
Company:
E&b technologies 2012 to Sep 2018
Position:
Managing partner
Education
Degree:
Doctorates, Doctor of Philosophy
School / High School:
Uc Irvine 1980 to 1986
Specialities:
Biology
Skills
Biotechnology • Drug Development • Clinical Development • Pharmaceutical Industry • Neuroscience • Drug Discovery • Clinical Trials • Biopharmaceuticals • Life Sciences • Ophthalmology • Lifesciences • Technology Transfer • Oncology • Cro • Regulatory Submissions • Commercialization • Fda • Regulatory Affairs • Pharmacology • Stem Cells • Cancer • Gcp • Ctms • R&D • Immunology • Therapeutic Areas • Infectious Diseases • Regenerative Medicine • Ind • Entrepreneurship • Medical Affairs • Drug Delivery • Vaccines • Business Relationship Management • Pharmaceuticals • Biomarkers
Emails
Industries
Pharmaceuticals
Resumes
Resumes
President, Chief Executive Officer And Founder
View pageLocation:
San Diego, CA
Industry:
Pharmaceuticals
Work:
E&B Technologies 2012 - Sep 2018
Managing Partner
Eveleth Consulting 2012 - Dec 2016
Consultant
Cavtherx Nov 2014 - Oct 2016
President, Chief Executive Officer and Founder
Trefoil Therapeutics Nov 2014 - Oct 2016
President, Chief Executive Officer and Founder
Pfizer 1999 - Mar 2012
Vice President
Managing Partner
Eveleth Consulting 2012 - Dec 2016
Consultant
Cavtherx Nov 2014 - Oct 2016
President, Chief Executive Officer and Founder
Trefoil Therapeutics Nov 2014 - Oct 2016
President, Chief Executive Officer and Founder
Pfizer 1999 - Mar 2012
Vice President
Education:
Uc Irvine 1980 - 1986
Doctorates, Doctor of Philosophy, Biology University of Connecticut 1974 - 1978
Bachelors, Bachelor of Science, Biology
Doctorates, Doctor of Philosophy, Biology University of Connecticut 1974 - 1978
Bachelors, Bachelor of Science, Biology
Skills:
Biotechnology
Drug Development
Clinical Development
Pharmaceutical Industry
Neuroscience
Drug Discovery
Clinical Trials
Biopharmaceuticals
Life Sciences
Ophthalmology
Lifesciences
Technology Transfer
Oncology
Cro
Regulatory Submissions
Commercialization
Fda
Regulatory Affairs
Pharmacology
Stem Cells
Cancer
Gcp
Ctms
R&D
Immunology
Therapeutic Areas
Infectious Diseases
Regenerative Medicine
Ind
Entrepreneurship
Medical Affairs
Drug Delivery
Vaccines
Business Relationship Management
Pharmaceuticals
Biomarkers
Drug Development
Clinical Development
Pharmaceutical Industry
Neuroscience
Drug Discovery
Clinical Trials
Biopharmaceuticals
Life Sciences
Ophthalmology
Lifesciences
Technology Transfer
Oncology
Cro
Regulatory Submissions
Commercialization
Fda
Regulatory Affairs
Pharmacology
Stem Cells
Cancer
Gcp
Ctms
R&D
Immunology
Therapeutic Areas
Infectious Diseases
Regenerative Medicine
Ind
Entrepreneurship
Medical Affairs
Drug Delivery
Vaccines
Business Relationship Management
Pharmaceuticals
Biomarkers
Business Records
Name / Title
Company / Classification
Phones & Addresses
Trefoil Therapeutics
Pharmaceuticals
Pharmaceuticals
868 Almondwood Way, San Diego, CA 92130
President
Associated Architects, PC
Architectural. · Architects · Architectural Svcs
Architectural. · Architects · Architectural Svcs
16 Spg Ln, Farmington, CT 06032
206 Main St, Unionville, CT 06085
(860) 677-2801, (860) 676-0627
206 Main St, Unionville, CT 06085
(860) 677-2801, (860) 676-0627
Publications
Us Patents
Method Of Using Cox-2 Inhibitors In The Treatment And Prevention Of Ocular Cox-2 Mediated Disorders
View pageUS Patent:
20020128267, Sep 12, 2002
Filed:
May 4, 2001
Appl. No.:
09/849683
Inventors:
Rebanta Bandyopadhyay - Portage MI, US
David Eveleth - East Brunswick NJ, US
Thomas Van Haarlem - Clinton NJ, US
Tugrul Kararli - Skokie IL, US
Satish Singh - Portage MI, US
David Eveleth - East Brunswick NJ, US
Thomas Van Haarlem - Clinton NJ, US
Tugrul Kararli - Skokie IL, US
Satish Singh - Portage MI, US
International Classification:
A61K031/415
A61K031/50
A61K031/12
A61K031/353
A61K031/50
A61K031/12
A61K031/353
US Classification:
514/247000, 514/406000, 514/456000, 514/471000, 514/684000
Abstract:
The present invention provides methods for the treatment and prevention of ocular COX-2 mediated disorders using COX-2 inhibitors.
Method Of Using Cox-2 Inhibitors In The Treatment And Prevention Of Ocular Cox-2 Mediated Disorders
View pageUS Patent:
20040058926, Mar 25, 2004
Filed:
Sep 22, 2003
Appl. No.:
10/332320
Inventors:
Rebanta Bandyopadhyay - Portage MI, US
David Eveleth - East Brunswick NJ, US
Tom Van Haarlem - Lebannon NJ, US
Tugrul Kararli - Skokie IL, US
Satish Singh - Portage MI, US
David Eveleth - East Brunswick NJ, US
Tom Van Haarlem - Lebannon NJ, US
Tugrul Kararli - Skokie IL, US
Satish Singh - Portage MI, US
International Classification:
A61K031/50
A61K031/415
A61K031/365
A61K031/18
A61K031/415
A61K031/365
A61K031/18
US Classification:
514/247000, 514/406000, 514/473000, 514/602000
Abstract:
The present invention provides methods for the treatment and prevention of ocular COX-2 mediated disorders using COX-2 inhibitors.
Alkaline And Acid Phosphatase Inhibitors In Treatment Of Neurological Disorders
View pageUS Patent:
55677240, Oct 22, 1996
Filed:
Jun 1, 1994
Appl. No.:
8/252109
Inventors:
Judith A. Kelleher - Irvine CA
David D. Eveleth - Mission Viejo CA
David D. Eveleth - Mission Viejo CA
Assignee:
Cortex Pharmaceuticals, Inc. - Irvine CA
International Classification:
A61K 3138
US Classification:
514368
Abstract:
The present invention provides a method of inhibiting. beta. -amyloid toxicity in brain cells. The method includes administering to the cells an amount of an alkaline phosphatase inhibitor which is pharmacologically effective to reduce degeneration in the cells. Methods of treatment of peripheral neuropathy are also provided using acid or alkaline phosphatase inhibitors.
Methods For Detecting Cellular Pathology By Assaying Spectrin And Spectrin Breakdown Products
View pageUS Patent:
51186063, Jun 2, 1992
Filed:
Jul 26, 1990
Appl. No.:
7/558700
Inventors:
Gary S. Lynch - Irvine CA
Peter A. Seubert - San Mateo CA
David D. Eveleth - Irvine CA
Peter A. Seubert - San Mateo CA
David D. Eveleth - Irvine CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12Q 100
G01N 3353
G01N 33566
G01N 2400
G01N 3353
G01N 33566
G01N 2400
US Classification:
435 71
Abstract:
The invention provides a method for the detection of cellular pathology by means of an immunoassay to determine the presence of stable breakdown products, termed BDP's or BDP1 and BDP2, of the cytoskeleton component spectrin. In one aspect of the invention, the components from a sample of spectrin-containing cells are physically separated, as by exposure to an electric field, in such a way that BDP and spectrin are separated. Antibodies reactive with BDP are then contacted with the separated sample, and their binding to that portion of the sample containing any BDP determined. In another aspect of the invention, an assay, such as an ELISA assay, is performed to detect total spectrin immunoreactivity as an indication of cellular death or degradation.